Ellen S. de Morrée

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer

Robert J. van Soest, Martin E. van Royen, Ellen S. de Morrée et al. · European Journal of Cancer · 2013 · 203 citations

Urology, Oncology, Medicine +7

Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer

Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam et al. · European Urology · 2014 · 130 citations

Urology, Medicine, Pharmacology +9

Genistein induces breast cancer-associated aromatase and stimulates estrogen-dependent tumor cell growth in in vitro breast cancer model

Majorie B.M. van Duursen, Sandra M. Nijmeijer, Ellen S. de Morrée et al. · Toxicology · 2011 · 77 citations

Breast Oncology, Chemoprevention Strategy, Medicine +9

Loss of SLCO1B3 drives taxane resistance in prostate cancer

Ellen S. de Morrée, René Böttcher, Robert J. van Soest et al. · British Journal of Cancer · 2016 · 64 citations · Full text

The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer

Robert J. van Soest, Annemieke J.M. Nieuweboer, Ellen S. de Morrée et al. · European Journal of Cancer · 2015 · 63 citations

Urology, Oncology, Medicine +5